Max Healthcare Institute Limited (MAXHEALTH): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Max Healthcare Institute Limited, explained in plain English.
- Max Healthcare Institute Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- MAXHEALTH closed at ₹1,081.00 on 20 November 2026.
- Over the past year the shares are down 8.5%, trading between ₹797.00 and ₹1,185.40.
- Reported fundamentals show return on equity of 12.79%, a net margin of 15.1%, debt to equity of 32.91.
- Our Pulse grade checklist scores it C (50/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 27.08% with a maximum drawdown of -29.91% and a beta of 0.7 against NIFTY 50.
- Recent coverage: Market winners: Max Healthcare, Deepak Fertilisers among 10 stocks that surged up to 14% in last week
- Recent coverage: Max Healthcare among 10 Nifty stocks rallied up to 22% in 1 month. Did you miss the rally?
- Recent coverage: Hospital stocks in focus: Max Healthcare, Aster DM, Fortis surge up to 7%
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare · Medical Care Facilities
Max Healthcare Institute Limited (MAXHEALTH)
₹947.1
▲ 0.8 (+0.08%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Neutral momentum · 3/51M
+10.00%
3M
-6.53%
6M
-7.70%
1Y
-13.74%
Where it sits in its 52-week range
36%Below 52-week high
19.8%
16.2% above the low
Momentum read
Neutral
3/5 checks passed
52-wk high
₹1,181.1
52-wk low
₹815
Market cap
₹92,184 Cr
P/E (trailing)
67.0
Dividend yield
—
ROE
12.79%
Profit margin
15.1%
Revenue growth
20.3%
Price / Book
8.14
Debt / Equity
32.91
EPS (TTM)
14.13
Book value
₹116.34
Beta
0.67
Pulse grade: D, 43 out of 100
Momentum
C- ✓Trading above 50-day average
- ✕Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
F- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
C- ✕Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (13.82%)
Safety
D- ✕Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹2,569 crore · net profit ₹415 crore · margin 16.2%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
MAXHEALTH headlines
No MAXHEALTH stories right now.
MAXHEALTH filings & announcements
MAXHEALTH, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
26.26%
Sharpe ratio
-0.76
Sortino ratio
-1.04
Max drawdown
-31%
Daily VaR (95%)
-2.79%
CAGR (1Y)
-15.62%
Return skew
0.08
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.